Henry Murray

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. ncbi Prevention of relapse after chemotherapy in a chronic intracellular infection: mechanisms in experimental visceral leishmaniasis
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Immunol 174:4916-23. 2005
  2. ncbi Leishmaniasis in the United States: treatment in 2012
    Henry W Murray
    Department of Medicine, Weill Cornell Medical College, New York, New York 10065, USA
    Am J Trop Med Hyg 86:434-40. 2012
  3. ncbi Interleukin 10 receptor blockade--pentavalent antimony treatment in experimental visceral leishmaniasis
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, Box 136, 1300 York Avenue, NY 10021, USA
    Acta Trop 93:295-301. 2005
  4. ncbi Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, Box 136, 1300 York Ave, New York, New York 10021, USA
    Infect Immun 73:3903-11. 2005
  5. ncbi Advances in leishmaniasis
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, New York, USA
    Lancet 366:1561-77. 2005
  6. ncbi Visceral Leishmania donovani infection in interleukin-13-/- mice
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Infect Immun 74:2487-90. 2006
  7. ncbi Responses to Leishmania donovani in mice deficient in both phagocyte oxidase and inducible nitric oxide synthase
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Am J Trop Med Hyg 74:1013-5. 2006
  8. ncbi Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Infect Immun 74:4370-4. 2006
  9. ncbi Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice
    Henry W Murray
    Department of Medicine, Weill Cornell Medical College, New York, New York 10065, USA
    Infect Immun 76:4088-91. 2008
  10. ncbi Treatment of visceral leishmaniasis in 2004
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Am J Trop Med Hyg 71:787-94. 2004

Research Grants

  1. HOST IMMUNOREGULATION OF ANTILEISHMANIAL CHEMOTHERAPY
    Henry Murray; Fiscal Year: 2005
  2. HOST IMMUNOREGULATION OF ANTILEISHMANIAL CHEMOTHERAPY
    Henry Murray; Fiscal Year: 2000
  3. Host Immunoregulation of Response to Antileishmanial Chemotherapy
    Henry Murray; Fiscal Year: 2007
  4. MONONUCLEAR PHAGOCYTE KILLINGS OF LEISHMANIA PARASITES
    Henry Murray; Fiscal Year: 1980
  5. MONONUCLEAR PHAGOCYTE KILLING OF LEISHMANIA PARASITES
    Henry Murray; Fiscal Year: 1993
  6. Immunochemotherapy in Visceral Leishmaniasis
    Henry W Murray; Fiscal Year: 2010

Collaborators

Detail Information

Publications28

  1. ncbi Prevention of relapse after chemotherapy in a chronic intracellular infection: mechanisms in experimental visceral leishmaniasis
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Immunol 174:4916-23. 2005
    ..Posttreatment, either CD8 or CD4 cells can direct the response, IL-12 is not required, and iNOS and phox, the activated macrophage's primary IFN-gamma-inducible leishmanicidal pathways, both become dispensable...
  2. ncbi Leishmaniasis in the United States: treatment in 2012
    Henry W Murray
    Department of Medicine, Weill Cornell Medical College, New York, New York 10065, USA
    Am J Trop Med Hyg 86:434-40. 2012
    ....
  3. ncbi Interleukin 10 receptor blockade--pentavalent antimony treatment in experimental visceral leishmaniasis
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, Box 136, 1300 York Avenue, NY 10021, USA
    Acta Trop 93:295-301. 2005
    ..These results suggest the possibility of using mAb-induced IL-10R blockade to develop low-dose and/or short-course immunochemotherapeutic regimens in visceral leishmaniasis...
  4. ncbi Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, Box 136, 1300 York Ave, New York, New York 10021, USA
    Infect Immun 73:3903-11. 2005
    ..donovani infection...
  5. ncbi Advances in leishmaniasis
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, New York, USA
    Lancet 366:1561-77. 2005
    ..Current obstacles to realistic prevention and proper management include inadequate vector (sandfly) control, no vaccine, and insufficient access to or impetus for developing affordable new drugs...
  6. ncbi Visceral Leishmania donovani infection in interleukin-13-/- mice
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Infect Immun 74:2487-90. 2006
    ..By itself, interleukin-13 does not appear to materially influence acquired resistance in this intracellular infection...
  7. ncbi Responses to Leishmania donovani in mice deficient in both phagocyte oxidase and inducible nitric oxide synthase
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Am J Trop Med Hyg 74:1013-5. 2006
    ..Nevertheless, visceral infection was controlled post-treatment and did not recur. A phox/iNOS-independent macrophage mechanism, which was not triggered by L. donovani, emerges after chemotherapy...
  8. ncbi Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Infect Immun 74:4370-4. 2006
    ..Nevertheless, testing in IL-18(-/-) mice compared to wild-type mice and in IL-12p40(-/-) compared to IL-12p35(-/-) mice also suggested both early-acting (IL-18) and late-acting (IL-23) antileishmanial effects independent of IL-12...
  9. ncbi Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice
    Henry W Murray
    Department of Medicine, Weill Cornell Medical College, New York, New York 10065, USA
    Infect Immun 76:4088-91. 2008
    ..In this model of visceral leishmaniasis, IL-6 appears to act in a suppressive, macrophage-deactivating fashion, which identifies it as a potential target for therapeutic blockade...
  10. ncbi Treatment of visceral leishmaniasis in 2004
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Am J Trop Med Hyg 71:787-94. 2004
    ..g., affordable, and therefore, deployable), and how to translate promising experimental approaches into actual therapy remain difficult next steps in the treatment of kala-azar...
  11. ncbi Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis
    H W Murray
    Weill Medical College of Cornell University, New York, NY 10021, USA
    J Infect Dis 182:1497-502. 2000
    ..Thus, IL-12 regulates host IFN-gamma-dependent and -independent responses that permit and/or enhance the leishmanicidal activity of Sb...
  12. ncbi Tissue granuloma structure-function in experimental visceral leishmaniasis
    H W Murray
    Department of Medicine, Weill College of Cornell University, New York 10021, USA
    Int J Exp Pathol 82:249-67. 2001
    ....
  13. ncbi Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches
    H W Murray
    Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
    Int J Infect Dis 4:158-77. 2000
    ....
  14. ncbi Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation
    H W Murray
    Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Infect Immun 68:6294-9. 2000
    ....
  15. ncbi Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, New York, USA
    J Infect Dis 188:458-64. 2003
    ..However, because anti-IL-10R also released IFN-gamma-independent effects, IL-10 appears to act more broadly and suppresses multiple antileishmanial mechanisms...
  16. ncbi Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Antimicrob Agents Chemother 47:2513-7. 2003
    ..5-fold more AMB alone (three injections of 5 mg/kg; total dose, 15 mg/kg). These results suggest that strengthening the host Th1-cell response may be a strategy for the development of AMB-sparing regimens in visceral leishmaniasis...
  17. ncbi Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York 10021, USA
    Infect Immun 71:6453-62. 2003
    ....
  18. ncbi A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan
    Joseph L Amprey
    Department of Medicine, Weill College of Medicine, Cornell University, New York, NY 10021, USA
    J Exp Med 200:895-904. 2004
    ..Together, these data identify Leishmania surface glycoconjugates as potential glycolipid antigens and suggest an important role for the CD1d-NK T cell immune axis in the early response to visceral Leishmania infection...
  19. ncbi Progress in the treatment of a neglected infectious disease: visceral leishmaniasis
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Expert Rev Anti Infect Ther 2:279-92. 2004
    ....
  20. ncbi Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Infect Immun 70:6284-93. 2002
    ..IL-10's deactivating effects regulate outcome in experimental visceral leishmaniasis, and IL-10R blockade represents a potential immuno- and/or immunochemotherapeutic approach in this infection...
  21. ncbi Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions
    Shyam Sundar
    Kala azar Medical Research Center, Department of Medicine, Banaras Hindu University, Institute of Medical Sciences, Varanasi, India
    Clin Infect Dis 45:556-61. 2007
    ..daily administration) and dose (1 vs. 0.75 mg/kg) and to determine whether the duration of amphotericin B treatment in Bihar, India, can be shortened to 15 days...
  22. ncbi New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine
    Shyam Sundar
    Kala azar Medical Research Center, Department of Medicine, Banaras Hindu University, Institute of Medical Sciences, Varanasi, India
    Clin Infect Dis 47:1000-6. 2008
    ....
  23. ncbi Kala-azar--progress against a neglected disease
    Henry W Murray
    N Engl J Med 347:1793-4. 2002
  24. ncbi Availability of miltefosine for the treatment of kala-azar in India
    Shyam Sundar
    Institute of Medical Sciences, Banaras Hindu University, 6 SK Gupta Nagar, Lanka, Varanasi 221-005, India
    Bull World Health Organ 83:394-5. 2005
  25. ncbi Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations
    Shyam Sundar
    Kala azar Medical Research Center, Department of Medicine, Banaras Hindu University, Institute of Medical Sciences, Varanasi, India
    Clin Infect Dis 38:377-83. 2004
    ....
  26. ncbi Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody
    Shyam Sundar
    Kala azar Medical Research Center, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India
    J Clin Microbiol 44:251-3. 2006
    ..yielded comparable results for symptomatic infection and identified apparent subclinical infection in 15 to 32% of healthy residents in a region where visceral leishmaniasis is highly endemic...
  27. ncbi A novel defect in interferon-gamma secretion in patients with refractory nontuberculous pulmonary mycobacteriosis
    Amar Safdar
    Ann Intern Med 138:521. 2003
  28. ncbi Drugs against leishmaniasis: a synergy of technology and partnerships
    Antony J Davis
    Division of Infection and Immunity, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, 3050, Parkville, Australia
    Trends Parasitol 20:73-6. 2004
    ..A crucial component will be the forging of partnerships between the pharmaceutical industry and publicly funded scientists to ensure that the promise of the current revolution in biology lives up to our hopes and expectations...

Research Grants26

  1. HOST IMMUNOREGULATION OF ANTILEISHMANIAL CHEMOTHERAPY
    Henry Murray; Fiscal Year: 2005
    ..And Aim 3: Characterize immunostimulation in AmB's efficacy, and in recrudescent infection following AmB therapy, pinpoint the likely cytokine-driven T cell mechanism which prevents post-treatment relapse. ..
  2. HOST IMMUNOREGULATION OF ANTILEISHMANIAL CHEMOTHERAPY
    Henry Murray; Fiscal Year: 2000
    ..And 5. Test the rational application of combination immunochemotherapy in a model of uncontrolled visceral infection induced by a clinically relevant Th2 cell-associated state. ..
  3. Host Immunoregulation of Response to Antileishmanial Chemotherapy
    Henry Murray; Fiscal Year: 2007
    ..abstract_text> ..
  4. MONONUCLEAR PHAGOCYTE KILLINGS OF LEISHMANIA PARASITES
    Henry Murray; Fiscal Year: 1980
    ..These studies will provide an in depth assessment of the mechanisms underlying macrophage microbicidal activity toward intracellular Leishmania parasites...
  5. MONONUCLEAR PHAGOCYTE KILLING OF LEISHMANIA PARASITES
    Henry Murray; Fiscal Year: 1993
    ..donovani and other strains of Leishmania...
  6. Immunochemotherapy in Visceral Leishmaniasis
    Henry W Murray; Fiscal Year: 2010
    ..This project's objectives and experimental strategies also hold the promise of improving treatment in other similar infections in which host defense depends on optimally activating T cell- dependent immune mechanisms. ..